This study examined the effects of a new phosphodiesterase type 5 inhibitor, DA-8159, on erectile function associated with hypercholesterolemia. First of all, in order to investigate whether chronic administration of DA-8159 prevents the development of erectile dysfunction associated with hypercholesterolemia, male SD rats were divided into four groups (normal control, hypercholesterolemic control, DA-8159 5 or 20 mg/kg/day). Over a 5-month period, the animals were fed a 2% cholesterol diet and administered DA-8159 orally once a day. After 5 months, the electrostimulation-induced penile erection and the vascular function using acetylcholine-induced vasodilation with endothelium-intact aortic rings were examined. Furthermore, the plasma lipid profiles, endothelin and N G ,N G -dimethylarginine (asymmetrical dimethylarginine, ADMA) concentrations were measured. In order to investigate the acute treatment effect of DA-8159 on the erectile function in an established hypercholesterolemic model, additional animals were given a 2% cholesterol diet for 5 months without DA-8159. At the end of 5 months, the rats were divided into three groups (hypercholesterolemic control, DA-8159 0.3 or 1 mg/kg). DA-8159 was administered intravenously 1 min prior to the intracavernous pressure (ICP) measurement. In a chronic treatment study, while the hypercholesterolemic control showed a significantly lower erectile function, vascular reactivity, and increased plasma cholesterol, endothelin and ADMA concentration, the chronic DA-8159 treatment clearly restored the erectile responses by electric stimulation, preserved the potential of thoracic aortic relaxation in a dose-dependent manner, and significantly decreased the plasma endothelin and ADMA concentrations. In an acute treatment study, DA-8159 induced a dose-and frequency-dependent increase in ICP. The ICP/BP ratio and the corresponding AUC values, and the detumescence time were also significantly increased compared to the hypercholesterolemic control. These results suggest that DA-8159 is beneficial for erectile dysfunction in a rat hypercholesterolemic model and provided a rationale for the potential use of DA-8159 for treating erectile dysfunction secondary to hypercholesterolemia.
Introduction
Erectile dysfunction (ED) is defined as the inability to maintain or achieve a hard penis sufficient for a sexual intercourse. Although ED may result from psychogenic, organic (neurological, vasculogenic or hormonal causes), or mixed origin, the major cause of ED is the organic basis in approximately 80% of men. 1 Hypercholesterolemia is one of the major risk factors associated with the development of ED. In men, every mmol/l increase in the total cholesterol level results in a 1.32-fold increase in the risk of ED. 2 In studies using hypercholesterolemic rabbits, the impairment of the relaxation of the cavernous smooth muscle in response to endotheliummediated and endothelium-independent stimuli has been reported, and the reduction of the elevated serum cholesterol level has been shown to normalize the erectile function. 3, 4 Nehra et al 5 reported that rabbits fed a 0.5% cholesterol diet for 16 weeks significantly decreased the corporal smooth muscle content. This decrease in the cavernosal smooth muscle content is quantitatively similar to the reduction observed in humans with ED. 6, 7 The cholesterol diet-fed model is an established model of nontraumatic vascular injury and is commonly used to examine artherosclerosis. In this model, vascular injury begins with a breakdown in the endothelial integrity without gross structural changes. As the amount of endothelial injury increases, abnormalities become evident in the number and function of the vascular smooth muscle cells that surround the endothelium. 3, 8 Ultimately, hypercholesterolemia in men and animals causes the following: (i) a reduced inflow of blood to the penis, 8 (ii) an impairment in the NO-mediated endotheliumdependent corporal smooth muscle relaxation, 3, 4 and (iii) morphological alteration such as fibrosis and degeneration of the corporal smooth muscle cells, 6 resulting in ED. Recent reports have shown that the erectile response to electrostimulation were impaired in hypercholesterolemic rats 9, 10 or rabbits.
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DA-8159 is a novel phosphodiesterase type 5 (PDE5) inhibitor that shows pharmacokinetic profiles with a T max of 1.0-1.5 h and a T 1/2 of 11-13 h, which would confer unique clinical properties of both a rapid onset and long duration. [12] [13] [14] In addition, the isoenzyme selectivity profile for DA-8159 is similar to that of sildenafil but unlike tadalafil it does not inhibit PDE11. It enhances the penile responses in normal, diabetic and spinal cord-injured rabbits, via the selective inhibition of PDE5, which accelerates the degradation of cyclic guanosine monophosphate (cGMP). [15] [16] [17] [18] The present study was performed to investigate the effect of DA-8159 on erectile function in a hypercholesterolemic rat model of ED. Experimental groups and DA-8159 treatment. After acclimatization, the animals were randomized into four groups. Group A (normal control, n ¼ 8) was fed a normal diet. Group B (hypercholesterolemic control, n ¼ 8), Group C (DA-8159 5 mg/kg, n ¼ 8) and Group D (DA-8159 20 mg/kg, n ¼ 8) were fed a 2% cholesterol diet (Research Diets Inc., USA) for 5 months. DA-8159 was administered orally once a day for 5 months at the dose level of 5 or 20 mg/kg.
Materials and methods

Test materials
Effect on erectile function. At the end of the treatment period, the ICP of each rat was measured. Briefly, after anesthetizing the rats with sodium pentobarbital (50 mg/kg, i.p.), the penile skin was incised and the prepuce was degloved to expose completely the corpora cavernosa (CC). A 26-gauge needle connected to a polyethylene tube filled with physiological saline containing 50 IU/ml heparin was inserted into the CC on one side in order to measure the ICP. The carotid artery was cannulated in a similar manner to the polyethylene tube in order to monitor the mean arterial pressure continuously. These parameters were recorded on a polygraph and the data acquisition and calculation of the derived parameters were performed using an on-line computer system (Signal processor, USA). The major pelvic ganglion was exposed through a midline abdominal incision. A stainless-steel bipolar electrode (Type ON203-045, Unique Medical Co. Ltd, Japan) was carefully positioned around the pelvic ganglion. Electric stimulation was performed unilaterally at 2 and 10 Hz, for 60 s with a pulse duration of 5 ms and 3 V using a stimulator (Electrical Stimulator, HSE, USA). The stimulus interval was 10 min. These conditions were obtained as a result of a preliminary study designed to determine the optimal stimulatory conditions. The maximum ICP (mmHg), the detumescence time, the ratio of the ICP to the blood pressure (BP) and the area under the curve (AUC) of the ratio of the ICP to BP were measured. The detumescence time was taken to be the period from the termination of electric stimulation (10 Hz) to the time when the ICP returned to its mean baseline value.
Thoracic aorta relaxation in organ chamber. An in vitro organ chamber study was performed to 25 .0 mM, Ca-EDTA 0.016 mM and glucose 11.1 mM) immediately after a cervical dislocation. The aorta was then cut into 3 mm ring segments and mounted in a 10 ml organ bath chamber containing 10 ml of the Krebs-Hanseleit solution. The solution was aerated with 95% O 2 and 5% CO 2 , at a pH of 7.4 and maintained at 371C. The aortic rings were subjected to a resting tension of 2 g and allowed to equilibrate for a period of 60 min while being rinsed with Krebs-Hanseleit solution every 15 min. The changes in the isometric tension were measured using a Grass F-60 transducer (Narco Bio-system, USA), and were recorded on a physiograph (Trace 80, Narco Bio-system, USA). The strips were precontracted with norepinephrine (NEP) (3 Â 10
, and those that did not reach a steady tension were excluded from the study. After the equilibration period, the degree of relaxation of the aortic ring was assessed by adding acetylcholine (1-10 3 nM) cumulatively to the bathing medium. The degree of relaxations is expressed as a percentage of the reversal of the NEP-induced contraction. All the experiments were carried out in the endotheliumintact aortic rings.
Measurement of biochemical parameters. After completing the ICP measurements, the whole blood was collected via the cannulated right carotid artery into an EDTA tube and centrifuged at 5000 r.p.m. Freshly collected EDTA-plasma was stored at À201C until the assay. The plasma total cholesterol, the LDL cholesterol and the HDL cholesterol were analyzed using a Konelab 20i autoanalyzer (Labsystems Co., Finland). The endothelin level in the plasma was measured according to the instruction manual provided with the endothelin ELISA kit (Biomedica). The plasma ADMA concentration was determined using high-performance liquid chromatography (HPLC) according to a previously published method. 19 
Experiment 2. Acute treatment effect of DA-8159
Effect on erectile function. Apart from the experiment 1, additional 15 animals were allocated to feed a 2% cholesterol diet for 5 months in order to examine the acute treatment effect of DA-8159 on an established hypercholesterolemic ED. At the end of 5 months, the hypercholesterolemic rats were divided into three groups for ICP measurement (each n ¼ 5). DA-8159 was administered intravenously 1 min before the ICP measurement at a dose of 0 (vehicle), 0.3 or 1 mg/kg. The rats fed the normal diet were used as the normal control. All the other procedures used for the ICP measurements were performed using the same method as described above.
Statistical analysis
All the statistical analyses were performed using SigmaStat s for Windows 2.0. software (Jandel Corporation, USA). The ANOVA test was used for the comparisons between the experimental groups and within each test group. All the data are expressed as a mean7standard deviation (s.d.). The comparison between the group means was accomplished using a Dunnett multiple range test at a significance level of P ¼ 0.05.
Results
Experiment 1. Long-term treatment effect of DA-8159
Changes in erectile response in hypercholesterolemic rats. In normal rats, the baseline ICP was 13.671.7 mmHg ranging from 11.43 to 16.22 mmHg. Electrostimulation of the pelvic ganglion induced an increase in the ICP in a frequency-dependent manner. The mean maximum ICP was 47.97 11.4 mmHg at 2 Hz and 75.1713.0 mmHg at 10 Hz (Figure 1 ). The ICP/BP ratio also increased in a frequency-dependent manner after electric stimulation (59.0721.7% at 2 Hz and 77.8716.1% at 10 Hz) and the corresponding AUCs of the ICP/BP ratio were 1014872195 (2 Hz) and 1178972856 (10 Hz) ( Figure 2 ). The detumescence time at a stimulation frequency of 10 Hz was 471.37154.8 s (Figure 3) .
The baseline intracavernous pressure in the hypercholesterolemic rats ranged from 7.05 to 9.63 mmHg. The maximum ICP and the corresponding ICP/BP ratio after electric stimulation were significantly lower than the normal control at both frequencies (Figures 1 and 2 ). The maximum ICPs were 24.677.2 mmHg (2 Hz) and 49.5711.8 mmHg (10 Hz), and the ICP/BP ratio were 38.2712.7% (2 Hz) and 54.8712.8% (10 Hz), respectively. The AUCs of the ICP/BP was 768372618 (10 Hz) and the detumescence time was 353.07148.7 s, which is significantly different from the normal controls ( Figure 3 ).
Effects of DA-8159 on erectile function in hypercholesterolemic rats. In the hypercholesterolemic rats, the baseline ICP treated with DA-8159 was 10.172.4 mmHg (5 mg/kg) and 10.272.0 mmHg Effect of DA-8159 on ED KK Kang et al (20 mg/kg), respectively. Electrostimulation of the pelvic ganglion in the rats treated with DA-8159 resulted in a significant increase in the maximum ICP in a dose-and frequency-dependent manner (Figure 1) . The ICP/BP ratio also increased in a doseand frequency-dependent manner (Figure 2 ). In the group administered 5 mg/kg DA-8159, the ICP/BP ratio was 59.5721.0% (2 Hz) and 77.6715.8% (10 Hz), and in the group administered 20 mg/kg DA-8159, the ICP/BP ratio was 60.2716.8% (2 Hz) and 78.5713.5% (10 Hz), respectively. The corresponding AUCs increased after administering the DA-8159 and were statistically significant (Po0.05). Furthermore, the detumescence time was prolonged after administering the DA-8159 (479.47124.3 s at 5 mg/kg and 505.57114.5 s at 20 mg/kg) ( Figure 3) . The mean arterial pressure was constant, irrespective of the stimulation frequency, both in the two controls and the DA-8159 treatment group (data not shown).
Effect of DA-8159 on the thoracic aorta relaxation induced by acetylcholine. Figure 4 shows the thoracic aorta relaxation induced by the cumulative addition of acetylcholine (Ach). Ach (10 À9 -10 À6 M) caused the endothelium-dependent relaxation in a concentration-dependent manner in all groups. In the hypercholesterolemic groups, the endotheliumdependent relaxation was strongly decreased when compared with the normal control group. Effect of DA-8159 on ED KK Kang et al tion in a dose-dependent manner. The maximum relaxant effects were 53.075.2% (20 mg/kg) and 40.874.0% (5 mg/kg), respectively, which were significantly different from the hypercholesterolemic control and comparable to that of the normal control.
Measurement of biochemical parameters. At the end of the experimental period (5 months), the plasma cholesterol levels of animals fed a 2% cholesterol diet were significantly increased. There was no significant change in the plasma cholesterol levels treated with DA-8159. The plasma endothelin concentration in the hypercholesterolemic controls was higher than that of the normal control; however, the increase was not statistically significant. The DA-8159 treatment (20 mg/kg) significantly decreased the plasma endothelin concentration. On the other hand, the plasma ADMA concentration significantly increased in the hypercholesterolemic controls. The DA-8159 treatment significantly decreased the ADMA level in a dose-dependent manner (Table 1) .
Experiment 2. Acute treatment effect of DA-8159
Effect on erectile function. The intravenous administration of DA-8159 caused a significantly increase in the ICP in a doseand frequency-dependent manner. Low-frequency stimulation (2 Hz) after the 0.3 or 1 mg/kg DA-8159 administration resulted in a significant increase in the ICP (47.0712.7 mmHg at 0.3 mg/kg and 49.374.0 mmHg at 1 mg/kg), and the corresponding ICP/BP ratio was also significantly higher (64.37 19.0% at 0.3 mg/kg and 66.0711.9% at 1 mg/kg). A significantly higher ICP and the corresponding ICP/BP ratio were also observed after the highfrequency electrostimulation. The detumescence time was 182.0792.8 s prior to DA-8159 administration and 437.57161.3 s (0.3 mg/kg) and 447.57 144.5 s (1 mg/kg) after administration, which was significantly prolonged. Accordingly, the mean AUC value for the decay period after DA-8159 administration (10 Hz) was 1533873908 (0.3 mg/ kg) and 1973574868 (1 mg/kg), which was significantly larger than the hypercholesterolemic control (792972884). A significant increase in the AUC Effect of DA-8159 on ED KK Kang et al value was also observed at 2 Hz. The mean arterial pressure was constant, irrespective of the stimulation frequency, both before and after the DA-8159 treatment (data not shown).
Discussion
Hypercholesterolemia believed to be one of the greatest risk factors of vasculogenic ED because it induces an injury to the endothelial and vascular smooth muscle cells, resulting in an abnormal function in corporal tissues. 3, 5 With regard to animal models, the rabbit model has been extensively studied because feeding excessive amounts of cholesterol diet to rabbits induces the rapid development of abnormal vessel function, atherosclerosis and ultimately ED. 11, 20 However, recently, the rat model of hypercholesterolemic ED was developed and offers several advantages; the easy assessment of the erectile function and less anesthesia-related complications. 9, 10 First of all, this study examined the erectile function in rats fed a long-term cholesterol-enriched diet leading to the development of a well-defined ED, particularly decreasing the ICP. This is comparable to previous observations in rats fed a cholesterol-enriched diet. 9, 10 In addition, this study showed that hypercholesterolemia impaired the endothelium-mediated vascular relaxation, which also agree with earlier report of reduced endothelium-dependent vasodilation in a hypercholesterolemic animal model. 11 Furthermore, the plasma cholesterol, endothelin and ADMA concentrations were also increased. Similar results have been reported by Best et al 21 and Yu et al. 22 In general, it is well known that hypercholesterolemic disease is commonly associated with structural and functional modifications that can take place at the level of the endothelium, the vascular smooth muscle and the extracellular matrix of the blood vessel and/or carvernosal tissue. Therefore, alterations in the endothelium-dependent relaxation might be implicated with ED due to hypercholesterolemia. Taken together, these results demonstrate that the erectile response is decreased as a result of the development of hypercholesterolemia, although the morphological changes were not examined in this study.
Secondly, this study demonstrated that the erectile responses in the hypercholesterolemic rats after a chronic treatment with DA-8159 for 5 months appears to offer protection from the harmful effects of hypercholesterolemia and preserve the erectile function. The beneficial effect on the erectile function was not due to a reduction in the elevated plasma cholesterol level by DA-8159 as evidenced by the similar cholesterol levels between the DA-8159-treated and hypercholesterolemic control group. Indeed, DA-8159 was not expected to affect Hypercholesteolemic control (n ¼ 5) the systemic cholesterol levels directly. However, there was a clear and dose-dependent preservation in the level of aortic ring relaxation after the chronic administration of DA-8159, which means that DA-8159 can keep the endothelium-dependent relaxation to normal. In addition, the plasma endothelin and ADMA levels were significantly lower than that of the hypercholesterolemic control. Since hypercholesterolemia impairs the endothelium-mediated corpus cavernosum smooth muscle relaxation and vasodilation and contributes to the development of ED, 3, 23 it appears that the increased vascular relaxation by DA-8159 would reflect a change in or preservation from the diseased state of hypercholesterolemic to the normal contractile state. The plasma concentration of endothelin, a vasoconstrictor, and ADMA, an endogenous competitive inhibitor of nitric oxide, is associated with impaired endothelium-dependent vasodilation in animals and patients with atherosclerosis, and is responsible for endothelial dysfunction associated with vascular diseases. 22 Therefore, the decrease of plasma endothelin and ADMA concentration achieved by long-term treatment with DA-8159 contributes to the preservation of erectile function of DA-8159 via the improvement of endothelial function in hypercholesterolemic rats.
On the other hand, hypercholesterolemia causes ED by affecting not only the smooth muscle but also the nerve and blood vessels, and VEGF and Chinese herbal medicines preserved the erectile response by alleviating these changes.
9,10 PDE5 inhibitor has been shown to enhance the endothelium-dependent vasodilation and improve the endothelial dysfunction. 24 Indeed, Sildenafil preserves the intracorporal smooth muscle content and abrogates the development of the intracorporal fibrosis in humans. 25 In addition, it significantly increases the number of intracorporal endothelial cells and smooth muscle content when administered in combination with free radical scavengers. 26 It was also demonstrated that the long-term treatment of Sildenafil in ED patients on a daily basis might bring about a regression in ED or be a useful tool for curing ED. 27 Furthermore, a chronic treatment of DA-8159 partially prevented the development of ED in the diabetic rats by increasing the smooth muscle and endothelial cell content, decreasing the level of TGF-b1 overexpression, and eventually increasing the ICP. 28 Based on these results and references, it is believed that DA-8159 might protect the development of ED by preserving the endothelial function and morphological changes in the penile tissue, while the histomorphological changes were not examined in this study. Further investigation is required to determine how DA-8159 treatment preserves the erectile function.
Pharmacotherapy with PDE5 inhibitors for treating ED has undergone dramatic advances since the successful introduction of Sildenafil (Viagra s ). 29 Another two PDE5 inhibitors, Vardenafil (Levitra s ) and Tadalafil (Cialis s ), are now available as potent and effective treatments with an approximately 60-80% response rate. DA-8159 is also a potent and selective PDE5 inhibitor that can inhibit cGMP hydrolysis, thereby elevating the levels of this cyclic nucleotide. While the efficacy of DA-8159 in diabetic and spinal cord-injured animals has been demonstrated, the efficacy in hypercholesterolemic animals has not yet been established. Therefore, the erectile function was measured in order to determine the efficacy of DA-8159 in increasing the ICP after a single intravenous injection in an established rat hypercholesterolemic model. The results clearly demonstrated that an intravenous injection of DA-8159 significantly increased the erectile function in hypercholesterolemic rats. Significant increases in the maximum ICP, ICP/BP ratio and the corresponding AUC, and the prolongation of the decay time were observed in a dose-and frequency-dependent manner. This suggests that DA-8159 is an effective treatment for ED with hypercholesterolemia.
In summary, this study showed that the chronic treatment with the PDE5 inhibitor, DA-8159, preserved the erectile function in hypercholesterolemic rats, and its efficacy was associated with an improvement in the endothelial function. In addition, this study demonstrated that DA-8159 induced potent erectile responses in the rat hypercholesterolemic model. These results provide a rationale for the use of DA-8159 for treating ED associated with hypercholesterolemia.
